Rh disease remains a significant health challenge, particularly impacting expectant mothers and their newborns. In this episode of Science Bytes, Dr. Steven Spitalnik discusses the milestones in Rh disease treatment, the ongoing challenges and future opportunities to combat this condition.   About our Speaker Dr Spitalnik, MD is a Professor in the Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons of Columbia University, and a member of the Medical Staff at New York Presbyterian/Columbia.  He has authored over 250 publications and served as an investigator on ~30 grants and contracts including Principal investigator on ~20 of those grants. Additionally, he has sponsored more than 15 Training Grants.  Dr. Spitalnik is a member of multiple professional societies, including the Association for the Advancement of Blood and Biotherapies (AABB) and the International Society for Blood Transfusion (ISBT). He has served on multiple committees within these organizations and was on the Board of Directors for the AABB. He has received multiple society awards and was elected to the Hall of Fame of the AABB Foundation (previously the National Blood Foundation). Dr. Spitalnik is the Founding Member and Executive Director of the Worldwide Initiative for Rh Disease Eradication (WIRhE).